Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Usefulness of human epididymis protein 4 in predicting cytoreductive surgical outcomes for advanced ovarian tubal and peritoneal carcinoma.

Tang Z, Chang X, Ye X, Li Y, Cheng H, Cui H.

Chin J Cancer Res. 2015 Jun;27(3):309-17. doi: 10.3978/j.issn.1000-9604.2015.06.01.

2.
3.

Serum HE4: An Independent Prognostic Factor in Non-Small Cell Lung Cancer.

Lamy PJ, Plassot C, Pujol JL.

PLoS One. 2015 Jun 1;10(6):e0128836. doi: 10.1371/journal.pone.0128836. eCollection 2015.

4.

Comparison of specific ovarian tumor markers by elecsys analyzer 2010.

Hasanbegovic L, Alicelebic S, Sljivo N.

Acta Inform Med. 2015 Apr;23(2):86-9. doi: 10.5455/aim.2015.23.86-89. Epub 2015 Apr 14.

5.

Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer.

Zhu LC, Gao J, Hu ZH, Schwab CL, Zhuang HY, Tan MZ, Yan LM, Liu JJ, Zhang DY, Lin B.

Am J Cancer Res. 2015 Jan 15;5(2):830-43. eCollection 2015.

6.

Expression level of serum human epididymis 4 and its prognostic significance in human non-small cell lung cancer.

Jiang Y, Wang C, Lv B, Ma G, Wang L.

Int J Clin Exp Med. 2014 Dec 15;7(12):5568-72. eCollection 2014.

7.

The human epididymis protein 4 acts as a prognostic factor and promotes progression of gastric cancer.

Guo YD, Wang JH, Lu H, Li XN, Song WW, Zhang XD, Zhang WM.

Tumour Biol. 2015 Apr;36(4):2457-64. doi: 10.1007/s13277-014-2858-0. Epub 2014 Nov 29.

8.

Serum Human Epididymis Protein 4 (HE4) in the Differential Diagnosis of Peritoneal Tuberculosis: A Report of Two Cases.

Kabaca C, Dolgun ZN, Telci A, Karateke A.

Balkan Med J. 2014 Sep;31(3):270-1. doi: 10.5152/balkanmedj.2014.13326. Epub 2014 Sep 1. No abstract available.

9.

Ovarian cystectomy in endometriomas: Combined approach.

Unlü C, Yıldırım G.

J Turk Ger Gynecol Assoc. 2014 Aug 8;15(3):177-89. doi: 10.5152/jtgga.2014.1111. eCollection 2014. Review.

10.

In 2014, can we do better than CA125 in the early detection of ovarian cancer?

Cohen JG, White M, Cruz A, Farias-Eisner R.

World J Biol Chem. 2014 Aug 26;5(3):286-300. doi: 10.4331/wjbc.v5.i3.286. Review.

11.

Proteomic identification of fucosylated haptoglobin alpha isoforms in ascitic fluids and its localization in ovarian carcinoma tissues from Mexican patients.

Garibay-Cerdenares OL, Hernández-Ramírez VI, Osorio-Trujillo JC, Hernández-Ortíz M, Gallardo-Rincón D, Cantú de León D, Encarnación-Guevara S, Villegas-Pineda JC, Talamás-Rohana P.

J Ovarian Res. 2014 Feb 27;7:27. doi: 10.1186/1757-2215-7-27.

12.

HE4 (WFDC2) gene overexpression promotes ovarian tumor growth.

Moore RG, Hill EK, Horan T, Yano N, Kim K, MacLaughlan S, Lambert-Messerlian G, Tseng YD, Padbury JF, Miller MC, Lange TS, Singh RK.

Sci Rep. 2014 Jan 6;4:3574. doi: 10.1038/srep03574.

13.

Clinical efficacy of serum human epididymis protein 4 as a diagnostic biomarker of ovarian cancer: A pilot study.

Chung SH, Lee SY, Ju W, Kim SC.

Obstet Gynecol Sci. 2013 Jul;56(4):234-41. doi: 10.5468/ogs.2013.56.4.234. Epub 2013 Jul 15.

14.

HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival.

Jiang SW, Chen H, Dowdy S, Fu A, Attewell J, Kalogera E, Drapkin R, Podratz K, Broaddus R, Li J.

Int J Mol Sci. 2013 Nov 18;14(11):22655-77. doi: 10.3390/ijms141122655.

15.

Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses.

Pitta Dda R, Sarian LO, Barreta A, Campos EA, Andrade LL, Fachini AM, Campbell LM, Derchain S.

BMC Cancer. 2013 Sep 18;13:423. doi: 10.1186/1471-2407-13-423.

16.

Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis.

Yang Z, Wei C, Luo Z, Li L.

Onco Targets Ther. 2013 Jul 23;6:957-66. doi: 10.2147/OTT.S45681. Print 2013. Erratum in: Onco Targets Ther. 2014;7:135.

17.

The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer.

Anastasi E, Granato T, Falzarano R, Storelli P, Ticino A, Frati L, Panici PB, Porpora MG.

J Ovarian Res. 2013 Jul 1;6(1):44. doi: 10.1186/1757-2215-6-44.

18.

Anti-HE4 antibodies in infertile women and women with ovarian cancer.

Hellstrom I, Swisher E, Hellstrom KE, Yip YY, Agnew K, Luborsky JL.

Gynecol Oncol. 2013 Sep;130(3):629-33. doi: 10.1016/j.ygyno.2013.05.028. Epub 2013 May 28.

19.

Biomarker testing for ovarian cancer: clinical utility of multiplex assays.

Nolen BM, Lokshin AE.

Mol Diagn Ther. 2013 Jun;17(3):139-46. doi: 10.1007/s40291-013-0027-6. Review.

20.

HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines.

Li J, Chen H, Mariani A, Chen D, Klatt E, Podratz K, Drapkin R, Broaddus R, Dowdy S, Jiang SW.

Int J Mol Sci. 2013 Mar 15;14(3):6026-43. doi: 10.3390/ijms14036026.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk